HIV-1-infection
Showing 1 - 25 of 230
New Treatment Strategies in Eastern European Region and in
Recruiting
- HIV-1-infection
-
Cologne, Germany
- +3 more
Nov 10, 2023
HIV-1-infection Trial in Brazil, United States (ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3)
Not yet recruiting
- HIV-1-infection
- ChAdOx1.tHIVconsv1
- +7 more
-
San Diego, California
- +11 more
Oct 4, 2023
HIV-1-infection Trial (FMT capsules, Placebo capsules)
Not yet recruiting
- HIV-1-infection
- FMT capsules
- Placebo capsules
- (no location specified)
Aug 31, 2023
HIV-1-infection, Sexually Transmitted Diseases Trial in Madrid (Description)
Completed
- HIV-1-infection
- Sexually Transmitted Diseases
- Description
-
Madrid, SpainHospital Universitario Infanta Leonor
Aug 16, 2023
Observational PIC Destination Cohort
Not yet recruiting
- HIV-1-infection
- (no location specified)
Aug 14, 2023
HIV-1-infection, HIV Seropositivity Trial in Gent (Leucapheresis)
Not yet recruiting
- HIV-1-infection
- HIV Seropositivity
- Leucapheresis
-
Gent, Oost-Vlaanderen, BelgiumUZ Gent
Jul 25, 2023
HIV-1-infection, Metabolic Syndrome Trial (physical activity)
Not yet recruiting
- HIV-1-infection
- Metabolic Syndrome
- physical activity
- (no location specified)
Jun 6, 2023
HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)
Not yet recruiting
- HIV-1-infection
- ART
- +2 more
-
Mbeya, TanzaniaNational Institute for Medical Research-Mbeya Medical Resarch Ce
Jun 6, 2023
HIV-1-infection Trial (Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir))
Not yet recruiting
- HIV-1-infection
- Low-dose STP0404 (Pirmitegravir)
- +3 more
- (no location specified)
May 16, 2023
Optimising Cohorts for HIV Cure Interventions
Recruiting
- HIV-1-infection
- no intervention
-
Prahran, Victoria, AustraliaAlfred Health
May 1, 2023
HIV-1-infection Trial in New York, Philadelphia, Nashville (INO-6160, 2 mg, Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500
Recruiting
- HIV-1-infection
- INO-6160, 2 mg
- Trimer-4571 / 100 mcg 3M-052-AF (5 mcg) + Alum (500 mcg)
-
New York, New York
- +2 more
Apr 13, 2023
HIV-1-infection Trial in Pathum Wan (VRC07-523LS, PGDM1400LS, N-803)
Not yet recruiting
- HIV-1-infection
- VRC07-523LS
- +7 more
-
Pathum Wan, Bangkok, Thailand
- +1 more
Mar 8, 2023
HIV-1-infection Trial (Cabotegravir/Rilpivirine, Antiretroviral)
Recruiting
- HIV-1-infection
-
Kisumu, Kenya
- +6 more
Feb 1, 2023
HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency Trial in Minneapolis (FT538, Vorinostat)
Not yet recruiting
- HIV-1-infection
- +4 more
- FT538
- Vorinostat
-
Minneapolis, MinnesotaMasonic Cancer Center at University of Minnesota
Jan 31, 2023
HIV-1-infection Trial in Amsterdam (ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes)
Active, not recruiting
- HIV-1-infection
- ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes
-
Amsterdam, Noord-Holland, NetherlandsAmsterdam University Medical Centers, location AMC
Jan 31, 2023
Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)
Not yet recruiting
- Kaposi Sarcoma
- HIV-1-infection
- Pegylated liposomal doxorubicin
- Paclitaxel
- (no location specified)
Jan 20, 2023
HIV-1-infection, Antenatal Care Trial in Lilongwe (iNSC and Adherence supporter training)
Completed
- HIV-1-infection
- Antenatal Care
- iNSC and Adherence supporter training
-
Lilongwe, MalawiBwaila District Hospital
Jan 9, 2023
HIV-1-infection Trial in Aarhus (Venetoclax)
Not yet recruiting
- HIV-1-infection
-
Aarhus, DenmarkAarhus University Hospital
Jan 5, 2023
Abacavir and Lamivudine Anabolites
Completed
- HIV-1-infection
- Blood collection
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Jan 5, 2023
HIV-1-infection Trial in Umlazi (Vesatolimod, VRC07523LS, CAP256V2LS)
Recruiting
- HIV-1-infection
- Vesatolimod
- +2 more
-
Umlazi, South AfricaFRESH Clinical Research Site: Females Rising through Education,
Jan 4, 2023
HIV-1-infection Trial in Saint Louis (Biktarvy Tab)
Terminated
- HIV-1-infection
- Biktarvy Tab
-
Saint Louis, MissouriSouthampton Healthcare, Inc.
Jan 3, 2023